1. Home
  2. KLRA vs ADMA Comparison

KLRA vs ADMA Comparison

Compare KLRA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$14.84

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$9.45

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLRA
ADMA
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2026
2012

Fundamental Metrics

Financial Performance
Metric
KLRA
ADMA
Price
$14.84
$9.45
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$25.67
AVG Volume (30 Days)
719.9K
1.7M
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.35
Revenue
N/A
$42,219,783.00
Revenue This Year
N/A
$27.46
Revenue Next Year
N/A
$22.11
P/E Ratio
N/A
$27.26
Revenue Growth
N/A
43.85
52 Week Low
$15.15
$7.21
52 Week High
$23.82
$20.46

Technical Indicators

Market Signals
Indicator
KLRA
ADMA
Relative Strength Index (RSI) 36.75 50.05
Support Level N/A $9.23
Resistance Level $19.02 $10.24
Average True Range (ATR) 1.27 0.25
MACD -0.12 -0.04
Stochastic Oscillator 4.65 23.84

Price Performance

Historical Comparison
KLRA
ADMA

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: